Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis
- PMID: 2564113
- DOI: 10.1016/s0140-6736(89)91611-5
Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis
Abstract
The leukotrienes LTC4, D4, and E4 are potent bronchoconstrictor agents and are thought to have an important role in asthma. Urinary LTE4, a stable urinary end-product of LTC4 and LTD4, was measured, by means of high-performance liquid chromatography and radioimmunoassay. LTE4 excretion followed a log-normal distribution in twenty-nine healthy controls, with a geometric mean of 23.8 (95% confidence interval 19.9-28.2) ng/mmol creatinine. Urine was collected from eight atopic subjects for 3 h after antigen inhalation and a control urine collection was made a week later at the same time of day. Urinary LTE4 was significantly higher after antigen challenge than in the control sample (153.7 [87.1-271.3] vs 23.5 [13.7-69.5] ng/mmol creatinine; p less than 0.01). Urinary LTE4 was also measured in twenty patients with severe acute asthma and nine patients with seasonal allergic rhinitis. Mean urinary LTE4 was higher in the asthmatic patients (78.3 [46.5-131.8] ng/mmol creatinine) than in normal subjects (p less than 0.01), although there was substantial overlap into the normal range. The urinary LTE4 values of the rhinitis patients were within the normal range whether or not they had symptoms. LTC4 and LTD4 were also found in bronchoalveolar lavage fluid from one of the three atopic subjects challenged with antigen before lavage, and in a single patient who underwent lavage after admission with severe acute asthma. These studies provide evidence that leukotrienes are released in vivo in man after antigen challenge and in acute asthma.
Similar articles
-
Urinary leukotriene E4 in bronchial asthma.Eur Respir J. 1992 Jun;5(6):693-9. Eur Respir J. 1992. PMID: 1321055
-
Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.Am Rev Respir Dis. 1992 Jul;146(1):96-103. doi: 10.1164/ajrccm/146.1.96. Am Rev Respir Dis. 1992. PMID: 1320824
-
Urinary LTE4 excretion in antigen-provoked asthmatic patients treated with the inhaled LTD4 antagonist, L-648,051.Allergy. 1992 Dec;47(6):599-603. doi: 10.1111/j.1398-9995.1992.tb02381.x. Allergy. 1992. PMID: 1337423 Clinical Trial.
-
[Studies on the experimental allergic rhinitis induced by Japanese cedar pollen--role of cysteinyl leukotrienes in nasal allergic symptoms].Yakugaku Zasshi. 2003 Jan;123(1):1-8. doi: 10.1248/yakushi.123.1. Yakugaku Zasshi. 2003. PMID: 12607939 Review. Japanese.
-
Sulphidopeptide leukotrienes in asthma.Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:415-9. Adv Prostaglandin Thromboxane Leukot Res. 1991. PMID: 1847780 Review.
Cited by
-
Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets.Curr Allergy Asthma Rep. 2016 Jul;16(7):48. doi: 10.1007/s11882-016-0628-3. Curr Allergy Asthma Rep. 2016. PMID: 27333777 Free PMC article. Review.
-
Reduction in leukotriene B4 generation by bronchoalveolar lavage cells in asthma.Thorax. 1995 Jan;50(1):67-73. doi: 10.1136/thx.50.1.67. Thorax. 1995. PMID: 7886653 Free PMC article.
-
Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.Drugs. 1998 Jan;55(1):121-44. doi: 10.2165/00003495-199855010-00008. Drugs. 1998. PMID: 9463793 Review.
-
Clinical evidence with montelukast in the management of chronic childhood asthma.Drugs. 2000;59 Suppl 1:29-34; discussion 43-5. doi: 10.2165/00003495-200059001-00005. Drugs. 2000. PMID: 10741880 Review.
-
Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma.Thorax. 2002 Apr;57(4):323-7. doi: 10.1136/thorax.57.4.323. Thorax. 2002. PMID: 11923550 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical